Abstract: Telaglenastat (CB-839) is a first-in-class, orally bioavailable, and highly selective inhibitor of the glutaminase (GLS) enzyme, specifically targeting the GLS1 isoform. By disrupting glutamine metabolism—a critical metabolic dependency for many tumors—CB-839 deprives cancer cells of essential nutrients required for proliferation and survival. In the context of Renal Cell Carcinoma (RCC), CB-839 has demonstrated significant pharmacological activity and is currently being evaluated in multiple clinical trials. While its efficacy as a monotherapy is limited by compensatory metabolic resistance mechanisms, CB-839 shows substantial promise when used in combination with immune checkpoint inhibitors, targeted therapies, and radiotherapy. This review summarizes the pharmacological profile, molecular mechanisms, structure-activity relationships, current limitations, and future therapeutic perspectives of Telaglenastat in RCC.
1. Introduction
Metabolic reprogramming is a hallmark of cancer, with many tumors exhibiting a profound dependency on glutamine for survival and anabolic growth, a phenomenon known as "glutamine addiction" [13]. Glutaminase (GLS) is the rate-limiting enzyme in glutaminolysis, responsible for converting glutamine to glutamate, which subsequently fuels the tricarboxylic acid (TCA) cycle and provides building blocks for macromolecules [13]. To exploit this metabolic vulnerability, Calithera Biosciences developed Telaglenastat (CB-839), a potent, selective, and orally bioavailable small-molecule inhibitor of GLS [13][24]. CB-839 has shown notable antiproliferative efficacy across various malignancies, including kidney cancer, making it a primary candidate for targeted metabolic therapy in Renal Cell Carcinoma (RCC) [13].
2. Pharmacological Activity
In preclinical and clinical settings, CB-839 effectively reduces tumor glutamine consumption and increases systemic and tumor microenvironment (TME) glutamine concentrations [4]. This metabolic shift provides tumor-infiltrating T-cells with greater access to glutamine, enhancing their proliferation and activation without causing significant toxicity to the immune cells themselves [4]. In advanced RCC, CB-839 has been extensively evaluated in combination regimens. The Phase II ENTRATA trial investigated Telaglenastat in combination with the mTOR inhibitor everolimus in advanced RCC, demonstrating encouraging clinical activity and tolerability [8]. Additionally, Phase I/II trials (such as CX-839-004) have assessed its safety and efficacy in combination with the immune checkpoint inhibitor nivolumab, as well as with the tyrosine kinase inhibitor cabozantinib, for patients with advanced or metastatic RCC [2][8]. Preliminary results from these studies indicate that CB-839 does not add significant toxicity beyond that of the backbone therapies and can revitalize responses in pre-treated patients [2].
3. Molecular Mechanism of Action
Telaglenastat functions as a selective, noncompetitive allosteric inhibitor of the GLS1 enzyme [13]. It specifically binds to the dimer interface of the enzyme, preventing its activation [15]. CB-839 exclusively targets the products of the GLS1 gene, which include both the kidney-type glutaminase (KGA) and glutaminase C (GAC) isoforms, without affecting the liver-type glutaminase (GLS2) [15]. By inhibiting GLS1, CB-839 blocks the conversion of glutamine to glutamate, thereby starving the tumor cells of TCA cycle intermediates and halting the production of molecules necessary for cellular biosynthesis [13]. Furthermore, the resulting accumulation of glutamine in the TME helps overcome tumor immune evasion by restoring the nutrient balance required for optimal CD8+ T-cell activation and anti-tumor immunity [4][15].
4. Structure-Activity Relationship (SAR)
The structural design of CB-839 is critical to its potent and selective inhibitory profile. Crystal structure analyses have demonstrated that the molecule features a terminal electron-withdrawing trifluoromethoxy group [13]. This specific functional group plays a dual role: it increases the overall lipophilicity of the compound, and it enhances the electronegativity of the adjacent pyridazinyl nitrogen atoms [13]. These electronic modifications result in strengthened hydrogen bond interactions between the inhibitor and the GLS1 enzyme, securing the compound firmly at the allosteric dimer interface and ensuring robust, noncompetitive inhibition [13].
5. Current Limitations
Despite its targeted mechanism, a major limitation of CB-839 is its lack of robust single-agent activity [4]. When used as a monotherapy, tumor cells can rapidly develop resistance through compensatory metabolic rewiring [12]. One primary resistance mechanism involves the upregulation of asparagine synthetase, which increases intracellular asparagine levels to maintain amino acid uptake, mTORC1 activation, and protein synthesis despite glutamate deprivation [12]. Another compensatory pathway is the upregulation of pyruvate carboxylase, an enzyme that converts pyruvate into oxaloacetate, thereby providing an alternative route to replenish the TCA cycle independently of glutamine [12].
6. Future Perspectives
To overcome the limitations of monotherapy, the future of Telaglenastat in RCC lies in rational combination strategies. Combining CB-839 with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1) continues to be a highly promising avenue, as GLS inhibition remodels the metabolic TME to favor T-cell activation [4][15]. Furthermore, dual inhibition of metabolic pathways—such as combining CB-839 with mTOR inhibitors (everolimus) or other targeted agents (cabozantinib)—is actively being explored to block compensatory survival routes in RCC [8]. Additionally, preclinical evidence suggests that CB-839 could serve as a potent radiosensitizer. By increasing oxidative stress and impairing DNA repair, concurrent administration of CB-839 and radiotherapy may help overcome the classical radioresistance associated with RCC, potentially allowing for de-escalation of radiation doses and improved local control [20].
7. References
